The Food and Drug Administration has granted approval for a new over-the-counter naloxone nasal spray, making the life-saving opioid reversal medication more accessible than ever. The product, branded as NaloxQuick, will be available at pharmacies nationwide without a prescription starting May 2026.
Unlike previous OTC naloxone products, NaloxQuick features a simplified single-step delivery system and a shelf life of three years, addressing two major barriers to widespread adoption. The retail price is expected to be under $25 for a two-dose package.
Opioid overdose deaths in the United States exceeded 80,000 in 2025, and public health officials hope expanded naloxone access will help reverse this trend. "Every minute counts during an overdose," says Dr. Rachel Torres of the National Institute on Drug Abuse. "Having naloxone readily available can mean the difference between life and death."
Several major pharmacy chains have committed to stocking the product prominently alongside first aid supplies. Community organizations are also planning distribution campaigns in high-risk neighborhoods.
The approval represents a significant step in the federal government's strategy to combat the opioid crisis through harm reduction approaches.
